Purpose: To propose a positron emission tomography (PET)/computed tomography (CT) protocol including early-dynamic and late-phase acquisitions to evaluate graft patency and aneurysm diameter, detect endoleaks, and rule out graft or vessel wall inflammation after endovascular aneurysm repair (EVAR) in one examination without intravenous contrast medium. Technique: Early-dynamic PET/CT of the endovascular prosthesis is performed for 180 seconds immediately after intravenous injection of F-18-fluorodeoxyglucose. Data are reconstructed in variable time frames (time periods after tracer injection) to visualize the arterial anatomy and are displayed as PET angiography or fused with CT images. Images are evaluated in view of vascular abnormalities, graft configuration, and tracer accumulation in the aneurysm sac. Whole-body PET/CT is performed 90 to 120 minutes after tracer injection. Conclusion: This protocol for early-dynamic PET/CT and PET angiography has the potential to evaluate vascular diseases, including the diagnosis of complications after endovascular procedures.
Introduction
Endovascular aneurysm repair (EVAR) is the treatment of choice for the majority of patients with abdominal aortic aneurysms. 1, 2 Since complications including mechanical graft failure, migration, and endoleak formation can occur, regular follow-up examinations are necessary. 3 It has been shown that computed tomography (CT) angiography, contrast-enhanced ultrasound, and magnetic resonance imaging (MRI) are feasible modalities for this purpose, with the accuracy dependent on the endoleak type. 4 Quantitative, dynamic positron emission tomography/ computed tomography (PET/CT) has been widely used for perfusion studies in oncologic, brain, and cardiac imaging. [5] [6] [7] Late-phase PET/CT is a sensitive tool for detection of vessel wall inflammation. 8 PET angiography is a special application of early-dynamic PET that became possible with technical improvements in PET scanners, shorter acquisition times, and higher resolutions, allowing anatomical visualization of vascular anatomy. 9 This article presents a PET/CT protocol combining dynamic PET data, metabolic late-phase PET data, and morphological CT data that can be used as a follow-up examination in patients after EVAR. 
Technique
The PET/CT protocol includes an early-dynamic and a static late-phase PET/CT. The patient is positioned supine in the PET/CT system [Biograph mCT 40 (Siemens Healthcare, Erlangen, Germany); axial PET coverage 21.8 cm per bed position; 3-second temporal resolution possible)]. For attenuation correction and anatomical correlation, a low-dose CT of the abdomen and pelvic region desired for early dynamic PET/CT is acquired (1 bed position). The continuous PET acquisition is started simultaneously with the radiotracer administration [standard activity 250-300 MBq F-18 fluorodeoxyglucose (FDG) in 10 mL of 0.9% saline solution, flow 4 mL/s into an antecubital vein, followed by rinsing with 20 mL of saline solution] and continued for 180 seconds. The timing for a standard whole-body PET/CT examination is not as critical as for early-dynamic PET; whole-body scanning can be started 90 to 120 minutes after tracer application (acquisition time 2 minutes per bed position).
For visualization of the endovascular graft in the abdominal aorta and pelvic arteries, an initial 10-second time frame followed by 6 time frames of 15 seconds each are reconstructed (Siemens HD TrueX software, attenuation corrected, iterative, matrix 512×512). Depending on variable patient and blood flow characteristics, including circulation time and possible slow flow in the aneurysm, variable time frames can be reconstructed from the raw earlydynamic PET data to improve visualization (ie, several 20-second intervals or one 10-to 40-second interval after injection). With our equipment, a temporal resolution of 3 seconds is possible. The resulting images per time frame can be visualized in multiplanar reconstruction and maximal intensity projection modes and fused with anatomical CT images. Images are evaluated in view of vascular abnormalities, graft configuration, aneurysm diameter, and tracer accumulation in the aneurysm sac. During early-dynamic imaging, the radioactive tracer is still intravascular, which avoids misinterpretation or artifacts due to extravascular tracer accumulation, for instance, in the urinary bladder. On late-phase images, tracer accumulation along the endoprosthesis and/or the arterial wall would suggest graft inflammation and/or vasculitis, respectively.
The technique is demonstrated in an 88-year-old man with a history of EVAR 12 years ago who was referred to our department for a whole-body PET/CT examination because of persistent inflammation markers under antibiotic treatment for lower leg erysipelas. The glomerular filtration rate (GFR) was reduced to 47 mL/min/1.73 m 2 . Because of the renal failure, it was decided not to apply iodinated contrast but perform early-dynamic PET to visualize perfusion of the aorta and iliac arteries. The patient's blood glucose level at radiotracer administration was 6.4 mmol/L. PET angiography showed normal perfusion of the aortic endoprosthesis ( Figure 1 ). In later time frames, 2 foci of tracer accumulation were seen outside the prosthetic lumen ( Figure 1B) , but inside the aneurysm sac (Figure 2 ). The foci were not apparent on late-phase images and therefore did not represent focal inflammation but were suspicious for an endoleak. Compared with the most recent EVAR surveillance CT 6 years ago, the aneurysm diameter had increased from 4.7 to 5.7 cm. Because of these unexpected findings, on the following day a contrast-enhanced CT was performed after intravenous hydration; it showed intrasac contrast enhancement and confirmed the endoleak ( Figure  3 ; probably type IIb with reperfusion of the aneurysm through branch vessels). The late-phase PET/CT showed no evidence of prosthesis inflammation (not shown).
Discussion
Contrast-enhanced ultrasound, CT, or MRI are established modalities for evaluation of the vasculature, and particularly for EVAR follow-up. However, these contrast-enhanced studies may be difficult or contraindicated in patients with impaired renal function, allergies, or hyperthyroidism. Flow-sensitive MR sequences, which allow perfusion evaluation without intravenous contrast media, may be impossible due to metallic implants.
PET angiography aims to visualize the arterial anatomy in contrast to semiquantitative numerical measurements. The radioactive tracer is the intravascular contrast medium, which is differentiated from the non-radioactive background. As a relatively new method, PET angiography has been evaluated in abdominal and pelvic arteries, 10, 11 in which the negative predictive values for detection of hemodynamically relevant stenoses are 90% to 100%, but the spatial resolution of the resulting images is still limited and therefore insufficient for small or moving arteries.
Studies of temporal enhancement patterns in the aneurysm sac after EVAR have shown that peak enhancement of endoleaks is variable and may be missed by biphasic CT protocols with fixed contrast timing. 12 For early-dynamic PET/CT and PET angiography, the dynamic dataset is reconstructed retrospectively and can be adapted to the clinical query and individual circulation times. Performed in addition to a standard PET/CT done to evaluate prosthesis inflammation or other questions, no separate radioactive tracer application is necessary. Accordingly, it can be accomplished without incurring additional costs. The only absolute contraindication is pregnancy.
Conclusion
The presented case illustrates the potential of earlydynamic PET/CT and PET angiography for evaluation of vascular diseases, including the diagnosis of complications after endovascular procedures. If further studies reveal a sufficient accuracy of this modality, a possible post-EVAR PET/CT protocol may show graft patency, aneurysm size, evidence of endoleaks, and rule out graft inflammation without the need for iodinated contrast or additional costs compared with a standard late-phase PET/CT. It may develop to represent a backup modality for specific patients and circumstances.
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